Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;101(8):905-915.
doi: 10.1007/s00109-023-02336-1. Epub 2023 Jun 8.

Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy

Ranxun Chen  1 , Jinghong Dai  2
Affiliations
Review

Lipid metabolism in idiopathic pulmonary fibrosis: From pathogenesis to therapy

Ranxun Chen et al. J Mol Med (Berl). 2023 Aug.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic irreversible interstitial lung disease characterized by a progressive decline in lung function. The etiology of IPF is unknown, which poses a significant challenge to the treatment of IPF. Recent studies have identified a strong association between lipid metabolism and the development of IPF. Qualitative and quantitative analysis of small molecule metabolites using lipidomics reveals that lipid metabolic reprogramming plays a role in the pathogenesis of IPF. Lipids such as fatty acids, cholesterol, arachidonic acid metabolites, and phospholipids are involved in the onset and progression of IPF by inducing endoplasmic reticulum stress, promoting cell apoptosis, and enhancing the expression of pro-fibrotic biomarkers. Therefore, targeting lipid metabolism can provide a promising therapeutic strategy for pulmonary fibrosis. This review focuses on lipid metabolism in the pathogenesis of pulmonary fibrosis.

Keywords: Cholesterol; Fatty acids; Idiopathic pulmonary fibrosis; Lipid metabolism.

PubMed Disclaimer

References

    1. Ma H, Wu X, Li Y, Xia Y (2022) Research progress in the molecular mechanisms, therapeutic targets, and drug development of idiopathic pulmonary fibrosis. Front Pharmacol 13(963):054. https://doi.org/10.3389/fphar.2022.963054 - DOI
    1. Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, Patel H, Kreuter M (2021) Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res 22(1):197. https://doi.org/10.1186/s12931-021-01791-z - DOI - PubMed - PMC
    1. Lederer DJ, Martinez FJ (2018) Idiopathic pulmonary fibrosis. N Engl J Med 378(19):1811–1823. https://doi.org/10.1056/NEJMra1705751 - DOI - PubMed
    1. Zheng Q, Cox IA, Campbell JA, Xia Q, Otahal P, de Graaff B, Corte TJ, Teoh AKY, Walters EH, Palmer AJ (2022) Mortality and survival in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. ERJ Open Res 8(1):00591–02021. https://doi.org/10.1183/23120541.00591-2021
    1. Fahy E, Cotter D, Sud M (1811) Subramaniam S (2011) Lipid classification, structures and tools. Biochim Biophys Acta 11:637–47. https://doi.org/10.1016/j.bbalip.2011.06.009 - DOI

Publication types

MeSH terms

LinkOut - more resources